We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AZN Astrazeneca Plc

52.00 (0.48%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  52.00 0.48% 10,914.00 10,918.00 10,922.00 11,018.00 10,858.00 10,946.00 2,402,054 16:35:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 28.43 169.28B
Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 10,862p. Over the last year, Astrazeneca shares have traded in a share price range of 9,461.00p to 12,390.00p.

Astrazeneca currently has 1,550,189,338 shares in issue. The market capitalisation of Astrazeneca is £169.28 billion. Astrazeneca has a price to earnings ratio (PE ratio) of 28.43.

Astrazeneca Share Discussion Threads

Showing 5676 to 5693 of 6150 messages
Chat Pages: Latest  234  233  232  231  230  229  228  227  226  225  224  223  Older
Remember brokers have their own agendas for their clients to buy/sell that chart showing as lower highs and lower lows?...
and this..

06/06/2022 | 07:38am EDT

Already positive, the research from JP Morgan and its analyst James Gordon still consider the stock as a Buy opportunity. The target price is unchanged and still at GBX 12000.

Was this downgraded by a broker today?Most likely it'll bounce back tomorrow.
AstraZeneca PLC said Monday that its Covid-19 vaccine has been granted approval in the European Union as a third dose booster for adults.

The pharmaceutical company said that its Vaxzevria vaccine can now be used as a third dose booster in patients previously given a vaccine schedule of either Vaxzevria or other EU-approved vaccines.

"Although more than 65% of the global population has received at least one dose of a Covid-19 vaccine, there remains a significant challenge to ensure people receive both their primary vaccine schedule and third-dose booster, and healthcare professionals now have greater flexibility in their choice of vaccine," AstraZeneca said.

Write to Jaime Llinares Taboada at; @JaimeLlinaresT

(END) Dow Jones Newswires

May 23, 2022 02:48 ET (06:48 GMT)

AstraZeneca was suffering from a broker downgrade, as Kepler Cheuvreux cut the parmaceutical stock to 'hold' from 'buy'. Astra shares were down 1.6%.

tp 10500p

Upwards start of upward movement.GDR potential multibagger. 300 nurses trying for new test .
AstraZeneca PLC said Thursday that its treatment for neuromyelitis optica spectrum disorder (NMOSD) Ultomiris met the primary endpoint in a Phase 3 clinical trial with a "statistically significant and clinically meaningful" reduction in the risk of relapse.

The Anglo-Swedish pharma giant said no relapse was observed in 58 patients during a treatment duration of 73 weeks.

"Every NMOSD relapse can have debilitating and irreversible consequences, so reducing relapses is critical," lead primary investigator in the trial Sean J. Pittock said.

The company said the data will be submitted to global health authorities as rapidly as possible.

Write to Michael Susin at

(END) Dow Jones Newswires

May 05, 2022 02:37 ET (06:37 GMT)

Dominic Lunn from Credit Suisse retains his positive opinion on the stock with a Buy rating.

The target price is unchanged at GBX 11000.

AstraZeneca's recent progress in drug innovations makes it a particularly strong choice for delivery of growth and inflation protection:
10,536 -0.25%

adrian j boris
29 Apr '22 - 09:45 - 5558 of 5559
0 0 0
What on earth is this guy chatting about?

Shows what poorly researched inaccurate nonsense is banded about online:

adrian j boris
AstraZeneca plans new US R&D hub as revenues rocket
Phil Taylor
April 29, 2022

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology drugs and heart failure therapy Farxiga.

The new site will be at Kendall Square and will serve as the new corporate headquarters for Alexion – which is currently based across the Charles River in Boston’s Seaport District – as well as housing around 1,500 R&D staff from AZ and Alexion in a new purpose-built space.

The site is expected to be completed in 2026 and according to AZ will benefit from its close proximity to several major academic, pharma and biotech institutions, providing access to “future talent”.

Boston and Cambridge are a life sciences hotspot in the US, home to more than 1,000 R&D-based biotechnology companies, with Kendall Square having the greatest density.

News of the investment comes shortly after AZ completed its new headquarters across the Atlantic in Cambridge in the UK, which was built at a cost of around $1.3 billion, three times the original estimate when the project was announced in 2013.

“Today’s announcement is a milestone moment following the acquisition of Alexion in July 2021,” said AZ chief executive Pascal Soriot as the company reported first-quarter sales up 60% to $11.4 billion.

“Our combined company has already successfully leveraged internal scientific synergies, and this move will act as a catalyst for even more external collaboration and innovation,” he added.

The healthy sales increase was bolstered by the timing of orders for AZ’s COVID-19 vaccine Vaxzevria, which made $1.1 billion in the quarter but is expected to make less of a contribution in the remainder of the year.

Another $469 million from Evusheld (tixagevimab and cilgavimab), the first drug to be authorised for prevention of COVID-19 infections, although that cam in slightly below analyst expectations.

Soriot also highlighted to performance of Farxiga (dapagliflozin), AZ’s SGLT2 inhibit for diabetes, heart failure and chronic kidney disease, which made $1 billion in the quarter, with a higher-than-predicted rise of 60% over the same period of 2021.

AZ’s oncology franchise also put in a good showing, collectively rising 14% to $3.4 billion, with highly-anticipated new HER2 drug Enhertu (trastuzumab deruxtecan) almost doubling to $76 million in the quarter, with potential new indications promising to accelerate growth further.

There was a 20% gain for Alexion’s Ultomiris (ravulizumab) to $419 million, welcome news as the drug is a successor to successor to Soliris (eculizumab) which slipped 5% to $990 million.

Ultomiris has just become the first and only long-acting C5 inhibitor approved for generalised myasthenia gravis in the US.

Don't miss your daily pharmaphorum news.

adrian j boris
What on earth is this guy chatting about?Shows what poorly researched inaccurate nonsense is banded about online:
AstraZeneca PLC said Wednesday that its Enhertu drug has been granted a breakthrough therapy designation in the U.S. for the treatment of an unresectable or metastic breast cancer.

The FTSE 100 pharma giant said that Enhertu has been now been granted five breakthrough therapy designations, including three in breast cancer and one in both lung and gastric cancers.

The trial showed significant improvement in survival, the company said.

AstraZeneca developed Enhertu with Japanese pharmaceutical company Daiichi Sankyo Co.

Write to Sabela Ojea at; @sabelaojeaguix

(END) Dow Jones Newswires

April 27, 2022 02:49 ET (06:49 GMT)

AstraZeneca PLC said Monday that its liver cancer treatment tremelimumab was accepted for priority review by U.S. federal health regulators.

The Anglo-Swedish pharmaceutical giant said the action date for the U.S. Food and Drug Administration's regulatory decision is expected in the fourth quarter of 2022.

The company said a Phase 3 study includes a dose of tremelimumab added to the immunotherapy Imfinzi, aiming to improve overall survival of patients with unresectable liver cancer.

"The Himalaya Phase III trial showed an unprecedented three-year overall survival in this setting with a single priming dose of tremelimumab added to Imfinzi, highlighting the potential for this regimen to improve longer-term survival outcomes," Susan Galbraith, AstraZeneca's executive vice president, oncology research and development, said.

Write to Michael Susin at

(END) Dow Jones Newswires

April 25, 2022 02:48 ET (06:48 GMT)

adrian j boris
Big news on the liver cancer trial this morning.
AstraZeneca PLC and Daiichi Sankyo Co. said Tuesday that Enhertu, a cancer treatment, has been accepted by the U.S. Food and Drug Administration for priority review for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease and the designation shortens the review period.

The pharmaceutical companies said the FDA based its decision on a pivotal Destiny-Lung01 trial which showed that Enhertu was the first HER2-directed therapy to show a strong and robust tumor response. It added that the FDA action date for their regulatory decision is during the third quarter of 2022.

The HER2 protein is expressed on the surface of many types of tumors and is one of many biomarkers expressed in breast cancer tumors.

"Enhertu is being further assessed in a comprehensive clinical development program evaluating efficacy and safety across multiple HER2-targetable cancers, including breast, gastric, lung and colorectal cancers," AstraZeneca said.

Write to Anthony O. Goriainoff at

(END) Dow Jones Newswires

April 19, 2022 02:40 ET (06:40 GMT)

Filled the gaps nicely on the chart
Chat Pages: Latest  234  233  232  231  230  229  228  227  226  225  224  223  Older

Your Recent History

Delayed Upgrade Clock